View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 18, 2019

Acrotech Biopharma to buy seven drugs from Spectrum for $300m

Aurobindo Pharma USA subsidiary Acrotech Biopharma has signed a definitive agreement to buy seven haematology and oncology drugs from Spectrum Pharmaceuticals for a consideration of up to $300m.

Aurobindo Pharma USA subsidiary Acrotech Biopharma has signed a definitive agreement to buy seven haematology and oncology drugs from Spectrum Pharmaceuticals for a consideration of up to $300m.

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

The terms of the agreement involve upfront payment of $160m in cash in and up to $140m in milestones.

Spectrum’s products covered under the deal are Fusilev (levoleucovorin), Zevalin (ibritumomab tiuxetan), Evomela (melphalan) for injection, Khapzory (levoleucovorin), Marqibo (vinCRIStine sulfate Liposome injection), Folotyn (pralatrexate injection) and Beleodaq (belinostat) for injection.

The products collectively generated $76.4m in sales during the first nine months of last year.

Spectrum’s decision to sell the portfolio is part of its strategy to focus on the development and commercialisation of new drugs for cancer.

The company plans to use the proceeds from the divestiture to bolster its pipeline and business.

Spectrum Pharmaceuticals president and CEO Joe Turgeon said: “This divestiture marks a major strategic shift for Spectrum to ensure laser-focus on novel, oncology drug development and commercialisation.

“The proceeds generated by the sale will significantly strengthen the financial position of the company, providing the capital to develop and commercialise our two late-stage pipeline assets, and placing us in a solid position to evaluate additional growth opportunities.”

“The proceeds generated by the sale will significantly strengthen the financial position of the company, placing us in a solid position to evaluate additional growth opportunities.”

The company is also downsizing its staff by nearly 40%. Majority of the affected employees will join Acrotech Biopharma .

Spectrum will retain a core group of commercial workforce to support the launch of its Rolontis and poziotinib products.

The acquisition has been approved by the boards of directors of both the companies. However, the deal is subject to regulatory approvals and is set to be completed by March this year.

In September last year, Aurobindo Pharma USA agreed to purchase generic and branded dermatology businesses of Novartis’ unit Sandoz for $900m and additional potential earn-outs worth $100m.

The deal also included Sandoz generic oral solids portfolio in the US.

Related Companies

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology